Retrophin (NASDAQ:RTRX) Share Price Crosses Below 50 Day Moving Average of $19.04

Retrophin Inc (NASDAQ:RTRX)’s share price crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $19.04 and traded as low as $20.08. Retrophin shares last traded at $20.31, with a volume of 11,567 shares changing hands.

A number of equities research analysts have commented on RTRX shares. BidaskClub raised Retrophin from a “sell” rating to a “hold” rating in a report on Thursday, March 14th. ValuEngine downgraded Retrophin from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. William Blair reissued an “outperform” rating on shares of Retrophin in a report on Wednesday, April 17th. Barclays began coverage on Retrophin in a report on Monday, April 22nd. They issued an “overweight” rating and a $36.00 target price for the company. Finally, Zacks Investment Research downgraded Retrophin from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $45.67.

The stock has a market capitalization of $832.05 million, a price-to-earnings ratio of -7.91 and a beta of 0.89. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.52 and a current ratio of 4.57. The company has a 50 day simple moving average of $19.09.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.41). The firm had revenue of $39.57 million for the quarter, compared to analyst estimates of $41.40 million. Retrophin had a negative return on equity of 41.38% and a negative net margin of 75.75%. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.14) EPS. Equities research analysts predict that Retrophin Inc will post -3.02 earnings per share for the current year.

In related news, CFO Laura Clague sold 2,500 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $18.25, for a total value of $45,625.00. Following the completion of the transaction, the chief financial officer now owns 14,750 shares of the company’s stock, valued at approximately $269,187.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Neil F. Mcfarlane sold 1,968 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $18.25, for a total transaction of $35,916.00. Following the completion of the transaction, the chief operating officer now directly owns 27,972 shares of the company’s stock, valued at approximately $510,489. The disclosure for this sale can be found here. Insiders have sold a total of 10,819 shares of company stock valued at $194,503 in the last ninety days. Corporate insiders own 4.32% of the company’s stock.

A number of hedge funds have recently made changes to their positions in RTRX. Bank of America Corp DE raised its stake in Retrophin by 114.4% in the 4th quarter. Bank of America Corp DE now owns 1,223,705 shares of the biopharmaceutical company’s stock valued at $27,693,000 after purchasing an additional 652,895 shares during the last quarter. Macquarie Group Ltd. raised its stake in Retrophin by 17.6% in the 4th quarter. Macquarie Group Ltd. now owns 2,265,924 shares of the biopharmaceutical company’s stock valued at $51,278,000 after purchasing an additional 339,588 shares during the last quarter. Two Sigma Investments LP raised its stake in Retrophin by 247.9% in the 4th quarter. Two Sigma Investments LP now owns 300,873 shares of the biopharmaceutical company’s stock valued at $6,809,000 after purchasing an additional 214,392 shares during the last quarter. D. E. Shaw & Co. Inc. raised its stake in Retrophin by 30.6% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 777,520 shares of the biopharmaceutical company’s stock valued at $17,595,000 after purchasing an additional 182,318 shares during the last quarter. Finally, Perceptive Advisors LLC raised its stake in Retrophin by 4.0% in the 4th quarter. Perceptive Advisors LLC now owns 3,342,038 shares of the biopharmaceutical company’s stock valued at $49,782,000 after purchasing an additional 129,167 shares during the last quarter.

Retrophin Company Profile (NASDAQ:RTRX)

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Recommended Story: What is meant by holder of record?

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.